BioSpace News Archive

Genetown

Synlogic Provides Corporate Update and Outlook for 2023

Synlogic, Inc., a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, summarized accomplishments for 2022 and outlined anticipated key milestones for 2023.

January 5, 2023
·
5 min read
Genetown

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

TScan Therapeutics, Inc. announced its 2023 clinical pipeline plans and highlighted recent corporate achievements.

January 5, 2023
·
8 min read
Genetown

EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

EyePoint Pharmaceuticals, Inc. announced a business update and key 2023 clinical timelines for its lead product candidate, EYP-1901.

January 5, 2023
·
9 min read
BioMidwest

Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits

Axogen, Inc. announced the independent publication of a comprehensive, retrospective clinical review comparing the meaningful recovery rates between allograft, autograft, and conduits using a meta-analysis methodology.

January 5, 2023
·
5 min read
BiondVax to Present at Biotech Showcase 2023

BiondVax Pharmaceuticals Ltd. announced that Mr. Amir Reichman, BiondVax’s CEO will present at the Biotech Showcase conference being held Jan. 9-11, 2023.

January 5, 2023
·
4 min read
Biotech Beach

ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa

ACELYRIN, INC. announced top-line 12-week open label data from Part A of a Phase 2b/3 trial of izokibep in patients with moderate-to-severe Hidradenitis Suppurativa.

January 5, 2023
·
3 min read
Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, announced a clinical trial collaboration and supply agreement with Merck.

January 5, 2023
·
3 min read
Business

Simnova and Orna Therapeutics Collaborate to Advance Orna’s Next Generation Circular RNA Technology in China

Shanghai Xianbo Biotech Co., Ltd. and BiTE-armed CAR-T cell therapies, and Orna Therapeutics today announced a collaboration agreement to discover, develop, and commercialize multiple potential therapeutics in the area of oncology.

January 5, 2023
·
3 min read
Business

Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth

Gustavo Mahler hired as the Chief Executive Officer of Ncardia and of Cellistic, and will join the Board of Directors.

January 5, 2023
·
3 min read
Drug Development

Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors.

January 5, 2023
·
6 min read